WO2003090721A3 - Verfahren zur herstellung von kristallen von arzneimittelwirkstoffen und deren verwendung in pharmazeutischen formulierungen - Google Patents

Verfahren zur herstellung von kristallen von arzneimittelwirkstoffen und deren verwendung in pharmazeutischen formulierungen Download PDF

Info

Publication number
WO2003090721A3
WO2003090721A3 PCT/EP2003/004153 EP0304153W WO03090721A3 WO 2003090721 A3 WO2003090721 A3 WO 2003090721A3 EP 0304153 W EP0304153 W EP 0304153W WO 03090721 A3 WO03090721 A3 WO 03090721A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments
active ingredients
pharmaceutical formulations
crystals
producing crystals
Prior art date
Application number
PCT/EP2003/004153
Other languages
English (en)
French (fr)
Other versions
WO2003090721A2 (de
Inventor
Detlef Grawe
Hagen Gerecke
Peter Hoesel
Annette Eichardt
Sabine Gliesing
Uwe Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to EP03747106A priority Critical patent/EP1523302A2/de
Priority to CA002480130A priority patent/CA2480130A1/en
Priority to MXPA04010466A priority patent/MXPA04010466A/es
Priority to JP2003587358A priority patent/JP2005535577A/ja
Priority to KR10-2004-7017080A priority patent/KR20050003388A/ko
Priority to IL16398403A priority patent/IL163984A0/xx
Priority to AU2003232490A priority patent/AU2003232490A1/en
Priority to BR0309358-1A priority patent/BR0309358A/pt
Publication of WO2003090721A2 publication Critical patent/WO2003090721A2/de
Priority to NO20045071A priority patent/NO20045071L/no
Publication of WO2003090721A3 publication Critical patent/WO2003090721A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Beschrieben wird ein Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, deren durchschnittliche Partikelgrösse in einem vorgegebenen Bereich liegen und deren maximale Partikelgrösse einen vorgegebenen Wert nicht überschreiten, wobei eine übersättigte Lösung während der Kristallisation einem Nassmahlen mittels einer Vorrichtung zum Nassmahlen unterzogen wird, wodurch eine Primärkornsuspension erhalten wird. Ferner werden nach diesem Verfahren erhältliche Kristalle sowie diese enthaltende pharmazeutische Formulierungen beschrieben.
PCT/EP2003/004153 2002-04-23 2003-04-22 Verfahren zur herstellung von kristallen von arzneimittelwirkstoffen und deren verwendung in pharmazeutischen formulierungen WO2003090721A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP03747106A EP1523302A2 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von arzneimittelwirstoffen, danach erh ltliche kristalle und deren verwendung in phar mazeutischen formulierungen
CA002480130A CA2480130A1 (en) 2002-04-23 2003-04-22 Method for producing crystals from active ingredients in medicaments and the use thereof in pharmaceutical formulations
MXPA04010466A MXPA04010466A (es) 2002-04-23 2003-04-22 Metodos para producir cristales a partir de ingredientes activos en medicamentos, cristales obtenidos de los mismos y el uso de los mismos en formulaciones farmaceuticas.
JP2003587358A JP2005535577A (ja) 2002-04-23 2003-04-22 医学的に有効な成分の結晶の製造法、この方法によって得られた結晶および得られた結晶の医薬製剤における使用
KR10-2004-7017080A KR20050003388A (ko) 2002-04-23 2003-04-22 의약의 활성 성분으로부터 결정을 생산하는 방법, 이방법을 통해 생산된 결정 및 약학적 제제에서 이의 용도
IL16398403A IL163984A0 (en) 2002-04-23 2003-04-22 Method for producing crystals from active ingredients in medicaments, crystals obtained by said method, and use thereof in pharmaceutical formulation
AU2003232490A AU2003232490A1 (en) 2002-04-23 2003-04-22 Method for producing crystals from active ingredients in medicaments, and the use thereof in pharmaceutical formulations
BR0309358-1A BR0309358A (pt) 2002-04-23 2003-04-22 Processo para fabricar cristais de substâncias ativas medicinais, cristais obtìveis com base nesse método e formulações farmacêuticas
NO20045071A NO20045071L (no) 2002-04-23 2004-11-22 Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218106.3 2002-04-23
DE10218106A DE10218106A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Publications (2)

Publication Number Publication Date
WO2003090721A2 WO2003090721A2 (de) 2003-11-06
WO2003090721A3 true WO2003090721A3 (de) 2005-02-24

Family

ID=29264786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004153 WO2003090721A2 (de) 2002-04-23 2003-04-22 Verfahren zur herstellung von kristallen von arzneimittelwirkstoffen und deren verwendung in pharmazeutischen formulierungen

Country Status (16)

Country Link
US (1) US20030215516A1 (de)
EP (1) EP1523302A2 (de)
JP (1) JP2005535577A (de)
KR (1) KR20050003388A (de)
CN (1) CN1812767A (de)
AU (1) AU2003232490A1 (de)
BR (1) BR0309358A (de)
CA (1) CA2480130A1 (de)
DE (1) DE10218106A1 (de)
IL (1) IL163984A0 (de)
MX (1) MXPA04010466A (de)
NO (1) NO20045071L (de)
PL (1) PL371518A1 (de)
RU (1) RU2004134321A (de)
WO (1) WO2003090721A2 (de)
ZA (1) ZA200409398B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
WO2007106768A2 (en) * 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
DE102010003711B4 (de) * 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
CA2947459A1 (en) 2014-05-13 2015-11-19 Akzo Nobel Chemicals International B.V. Process to crystallize chelating agents
CN108031142A (zh) * 2017-12-13 2018-05-15 上海合全药物研发有限公司 一种简化的利用湿磨来制备大量微晶种的装置及方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB838654A (en) * 1956-02-08 1960-06-22 Upjohn Co Steroids and the production thereof
US4412838A (en) * 1978-01-16 1983-11-01 Metallgesellschaft Aktiengesellschaft Process for recovering potassium chloride
US4997637A (en) * 1989-05-09 1991-03-05 Occidental Chemical Corporation Digestive crystallizing process and apparatus for purification of KC1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) * 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
CH627449A5 (de) * 1977-03-25 1982-01-15 Hoffmann La Roche Verfahren zur herstellung von mikrokristallinem vitamin a-acetat, sowie von trockenen, frei-fliessenden praeparaten, in welchen vitamin a-acetat in mikrokristalliner form vorliegt.
DE3014160A1 (de) * 1979-04-16 1980-10-30 Lummus Co Kristallisationsverfahren
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
DE4143631A1 (de) * 1991-05-30 1998-04-16 Dynamit Nobel Ag Zerkleinerung von pulverförmigen Initialsprengstoffen
DE4244466C2 (de) * 1992-12-24 1995-02-23 Pharmatech Gmbh Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB838654A (en) * 1956-02-08 1960-06-22 Upjohn Co Steroids and the production thereof
US4412838A (en) * 1978-01-16 1983-11-01 Metallgesellschaft Aktiengesellschaft Process for recovering potassium chloride
US4997637A (en) * 1989-05-09 1991-03-05 Occidental Chemical Corporation Digestive crystallizing process and apparatus for purification of KC1

Also Published As

Publication number Publication date
KR20050003388A (ko) 2005-01-10
CA2480130A1 (en) 2003-11-06
BR0309358A (pt) 2005-02-22
EP1523302A2 (de) 2005-04-20
NO20045071L (no) 2005-01-21
MXPA04010466A (es) 2004-12-13
CN1812767A (zh) 2006-08-02
ZA200409398B (en) 2006-06-28
DE10218106A1 (de) 2003-11-20
WO2003090721A2 (de) 2003-11-06
JP2005535577A (ja) 2005-11-24
AU2003232490A1 (en) 2003-11-10
PL371518A1 (en) 2005-06-27
RU2004134321A (ru) 2005-10-10
US20030215516A1 (en) 2003-11-20
IL163984A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
RU2004127916A (ru) Способ введения молекул glp-1
MXPA03010877A (es) Derivados de 2-anilin-pirimida como inhibidores de cinasa dependientes de ciclina.
MX2022016230A (es) Clorhidrato de (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-nmetilm etanamina cristalino y formulaciones de las mismas.
CA2290918A1 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2004033418A3 (en) Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
CA2369070A1 (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
WO2006027449A3 (fr) Compose pulverulent d'oxyde mixte de titane et de lithium dense, procede de fabrication d'un tel compose et electrode comportant un tel compose
IL163985A0 (en) Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulation
WO2004026836A3 (en) 1-pyridin-4-yl-urea derivatives
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete
AU2001250365A1 (en) Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
WO2002070464A3 (en) Hydrazones and their therapeutic use
WO2001098245A3 (en) Triphenyl compounds as interleukin-4 antagonists
WO2003090721A3 (de) Verfahren zur herstellung von kristallen von arzneimittelwirkstoffen und deren verwendung in pharmazeutischen formulierungen
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
WO2006127321A3 (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2002036158A8 (en) Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
ZA200409401B (en) Method for producing steroid crystals, crystals obtained by said method and their use in pharmaceutical formulations.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003747106

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1310/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 163984

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2480130

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003587358

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/010466

Country of ref document: MX

Ref document number: 1020047017080

Country of ref document: KR

Ref document number: 2003232490

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038092123

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004/09398

Country of ref document: ZA

Ref document number: 200409398

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2004134321

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047017080

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2003747106

Country of ref document: EP